Response

Affiliations

¹ Mayo Clinic, Rochester, MN. Electronic address: frantz.robert@mayo.edu.
² Actelion Pharmaceuticals US, Inc. South, San Francisco, CA.
³ Pulmonary Center, Boston University School of Medicine, Boston, MA.
⁴ University of Colorado, Denver, CO.
⁵ Intermountain Medical Center and the University of Utah School of Medicine, Salt Lake City, UT.
⁶ Houston Methodist Lung Cancer, Weill Cornell Medical College, Houston, TX.
⁷ Mayo Clinic, Rochester, MN.
⁸ former employee of ICON Clinical Research.
⁹ Allegheny General Hospital, Pittsburgh, PA.

Comment

Robert P Frantz et al. Chest. 2018 Nov.

. 2018 Nov;154(5):1262-1264.

doi: 10.1016/j.chest.2018.07.033.

¹ Mayo Clinic, Rochester, MN. Electronic address: frantz.robert@mayo.edu.
² Actelion Pharmaceuticals US, Inc. South, San Francisco, CA.
³ Pulmonary Center, Boston University School of Medicine, Boston, MA.
⁴ University of Colorado, Denver, CO.
⁵ Intermountain Medical Center and the University of Utah School of Medicine, Salt Lake City, UT.
⁶ Houston Methodist Lung Cancer, Weill Cornell Medical College, Houston, TX.
⁷ Mayo Clinic, Rochester, MN.
⁸ former employee of ICON Clinical Research.
⁹ Allegheny General Hospital, Pittsburgh, PA.

No abstract available

Comment on

Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.
Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Frantz RP, et al. Chest. 2018 Jul;154(1):126-135. doi: 10.1016/j.chest.2018.01.009. Epub 2018 Jan 31. Chest. 2018. PMID: 29355551 Free PMC article.
Untangling BNP and BMI: Does Obesity Limit the Predictive Capability of BNP in PAH?
Medrek SK, Melendres-Groves L. Medrek SK, et al. Chest. 2018 Nov;154(5):1262. doi: 10.1016/j.chest.2018.04.049. Chest. 2018. PMID: 30409363 No abstract available.